NEW YORK (GenomeWeb News) – Thermo Fisher Scientific will collaborate with Expression Pathology in applying their respective proteomic and microdissection technologies to measure cancer-related proteins in formalin-fixed paraffin-embedded tissue.

The collaboration will involve using Thermo Fisher's mass spectrometry technologies with Expression Pathology's laser microdissection and Liquid Tissue sample processing tools to study these proteins using an alternative to immunohistochemistry (IHC) and tissue morphology techniques.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.